Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Ventilation -112% Improvement Relative Risk ICU admission -53% Hospitalization time -17% c19hcq.org Babayigit et al. HCQ for COVID-19 LATE TREATMENT Favors HCQ Favors control
The association of antiviral drugs with COVID-19 morbidity: The retrospective analysis of a nationwide COVID-19 cohort
Babayigit et al., Frontiers in Medicine, doi:10.3389/fmed.2022.894126
Babayigit et al., The association of antiviral drugs with COVID-19 morbidity: The retrospective analysis of a nationwide.., Frontiers in Medicine, doi:10.3389/fmed.2022.894126
Aug 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 1,472 hospitalized patients in Turkey, showing a higher risk of ICU admission and ventilation with HCQ, without statistical significance.
risk of mechanical ventilation, 112.4% higher, RR 2.12, p = 0.21, treatment 63 of 1,378 (4.6%), control 6 of 94 (6.4%), adjusted per study, odds ratio converted to relative risk, multivariable.
risk of ICU admission, 52.8% higher, RR 1.53, p = 0.33, treatment 107 of 1,363 (7.9%), control 9 of 93 (9.7%), adjusted per study, odds ratio converted to relative risk, multivariable.
hospitalization time, 16.7% higher, relative time 1.17, p = 0.05, treatment 852, control 63.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Babayigit et al., 31 Aug 2022, retrospective, Turkey, peer-reviewed, mean age 51.9, 68 authors, study period 11 March, 2020 - 18 July, 2020.
Contact: habayram@ku.edu.tr.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: TYPE Original Research PUBLISHED 31 August 2022 DOI 10.3389/fmed.2022.894126 OPEN ACCESS EDITED BY Esmaeil Mortaz, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Iran The association of antiviral drugs with COVID-19 morbidity: The retrospective analysis of a nationwide COVID-19 cohort REVIEWED BY Burcin Halacli, Hacettepe University, Turkey Ahmed Mostafa, National Research Centre, Egypt Juliana Ferreira, University of São Paulo, Brazil *CORRESPONDENCE Hasan Bayram habayram@ku.edu.tr SPECIALTY SECTION This article was submitted to Pulmonary Medicine, a section of the journal Frontiers in Medicine RECEIVED 11 March 2022 ACCEPTED 11 August 2022 PUBLISHED 31 August 2022 CITATION Babayigit C, Kokturk N, Kul S, Cetinkaya PD, Atis Nayci S, Argun Baris S, Karcioglu O, Aysert P, Irmak I, Akbas Yuksel A, Sekibag Y, Baydar Toprak O, Azak E, Mulamahmutoglu S, Cuhadaroglu C, Demirel A, Kerget B, Baran Ketencioglu B, Ozger HS, Ozkan G, Ture Z, Ergan B, Avkan Oguz V, Kilinc O, Ercelik M, Ulukavak Ciftci T, Alici O, Nurlu Temel E, Ataoglu O, Aydin A, Cetiner Bahcetepe D, Gullu YT, Fakili F, Deveci F, Kose N, Tor MM, Gunluoglu G, Altin S, Turgut T, Tuna T, Ozturk O, Dikensoy O, Yildiz Gulhan P, Basyigit I, Boyaci H, Oguzulgen IK, Borekci S, Gemicioglu B, Bayraktar F, Elbek O, Hanta I, Kuzu Okur H, Sagcan G, Uzun O, Akgun M, Altinisik G, Dursun B, Cakir Edis E, Gulhan E, Oner Eyuboglu F, Gultekin O, Havlucu Y, Ozkan M, Sakar Coskun A, Sayiner A, Kalyoncu AF, Itil O and Bayram H (2022) The association of antiviral drugs with COVID-19 morbidity: The retrospective analysis of a nationwide COVID-19 cohort. Front. Med. 9:894126. doi: 10.3389/fmed.2022.894126 Frontiers in Medicine Cenk Babayigit 1 , Nurdan Kokturk 2 , Seval Kul 3 , Pelin Duru Cetinkaya 4,5 , Sibel Atis Nayci 6 , Serap Argun Baris 7 , Oguz Karcioglu 8 , Pinar Aysert9 , Ilim Irmak10 , Aycan Akbas Yuksel11 , Yonca Sekibag12 , Oya Baydar Toprak 5 , Emel Azak 13 , Sait Mulamahmutoglu12 , Caglar Cuhadaroglu14 , Aslihan Demirel15 , Bugra Kerget16 , Burcu Baran Ketencioglu17 , Hasan Selcuk Ozger9 , Gulcihan Ozkan18,19 , Zeynep Ture 20 , Begum Ergan 21 , Vildan Avkan Oguz 22 , Oguz Kilinc 21 , Merve Ercelik 23 , Tansu Ulukavak Ciftci2 , Ozlem Alici24 , Esra Nurlu Temel 25 , Ozlem Ataoglu 23 , Asena Aydin26 , Dilek Cetiner Bahcetepe26 , Yusuf Taha Gullu 27 , Fusun Fakili 28 , Figen Deveci29 , Neslihan Kose 30 , Muge Meltem Tor 31 , Gulsah Gunluoglu32 , Sedat Altin 32 , Teyfik Turgut29 , Tibel Tuna27 , Onder Ozturk 33 , Oner Dikensoy 34 , Pinar Yildiz Gulhan 23 , Ilknur Basyigit 7 , Hasim Boyaci 7 , Ipek Kivilcim Oguzulgen2 , Sermin Borekci 12 , Bilun Gemicioglu 12 , Firat Bayraktar35 , Osman Elbek 36 , Ismail Hanta5 , Hacer Kuzu Okur14 , Gulseren Sagcan14 , Oguz Uzun27 , Metin Akgun 16 , Goksel Altinisik 37 , Berna Dursun38 , Ebru Cakir Edis 39 , Erkmen Gulhan 40 , Fusun Oner Eyuboglu 41 , Okkes Gultekin 42 , Yavuz Havlucu 42 , Metin Ozkan 38 , Aysin Sakar Coskun 42 , Abdullah Sayiner 43 , A. Fuat Kalyoncu10 , Oya Itil 21 and Hasan Bayram 44,45* 1 Department of Pulmonary Medicine, Faculty of Medicine, Mustafa Kemal University, Antakya, Turkey, 2 Department of Pulmonary Medicine, Faculty of Medicine, Gazi University, Ankara, Turkey, 3 Department of Biostatistics, Faculty of Medicine, Gaziantep University, Gaziantep, Turkey, 4 Department of Pulmonary Medicine, Adana City Training and Research Hospital, University of Health Sciences, Adana, Turkey, 5 Department of..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit